University of California, San Francisco: Research to Revenue

University of California, San Francisco

Summit Venture Studio

Research to Revenue Report

Summit Venture Studio (SVS) Opportunities

SVS has identified 18 commercialization opportunities from University of California, San Francisco and scored them based on our proprietary metrics and rubrics.

The SVS model is to identify the top 1% of commercialization opportunities and start companies around them.

Please connect with SVS if you would like to engage with us in our startup and investment efforts.

Return on Research (ROR) Analysis

Commercialization Revenue per Research Dollar

Top Universities by Return on Research (ROR)

ROI Ratio: Commercialization Revenue ÷ Research Funding

University Innovation Analysis

Total Innovation Scores by Institution

Top Universities by Innovation Score

180+ High Innovation

150-179 Strong Innovation

130-149 Moderate Innovation

100-129 Emerging Innovation

130+ total score considered high innovation impact

SVS Innovation Index

Proprietary Assessment of University of California, San Francisco's Innovation Ecosystem
Score out of 100. Benchmark: Top 50 U.S. research institutions.
A score of 90/100 can be read "doing better than 90% of schools benchmarked"

Innovation Visibility

50/100

Definition: Media mentions, publication count, and global research visibility metrics

Startup Momentum

9/100

Definition: Growth in patents, funding, and startup formation

Ecosystem Strength

56/100

Definition: Tech transfer infrastructure and support systems

Innovation Legacy

A Timeline of Groundbreaking Discoveries

Innovation Timeline

Founded

1864

First Nobel

1949

First Patent

1971

First IPO

N/A

2022-2024

AI-driven drug discovery

2025

Today

Notable Commercialization Outcomes

Nobel Prizes

1990s

Human Genome

Contributed to genome sequencing

1990s

Insulin Innovation

Developed synthetic insulin

1996

Antiretroviral Drugs

Advanced HIV treatment drugs

2003

Cancer Immunotherapy

Pioneered CAR-T therapy research

2010s

CRISPR Advances

Applied gene-editing technology

2014

Competitive Benchmarking

University of California, San Francisco vs. Peer Research Universities

University of California, San Francisco vs Peers Comparison

Metric	University of California, San Francisco (FY2023)	Peer Average	Elite Average
Annual R&D Expenditure	$2,047M	$855M	$1,675M
New Inventions Disclosed	8	200	400
Startups Formed	9	7	10
Visibility Index	5	12	23
Licensing Revenue	$40M	$17M	$46M

Note: Peer Average = Median value among U.S. R1 research universities. Elite Average = Top 10 ranked U.S. research universities.

Emerging Opportunities

1. AI-Driven Diagnostics Revolutionizing Early Disease Detection

AI-powered diagnostic tools enable rapid, accurate disease identification, reducing healthcare costs and improving patient outcomes globally, with vast scalability and competitive edge.

2. Next-Gen Immunotherapies Targeting Resistant Cancers

Innovative immunotherapy platforms address treatment-resistant cancers, offering personalized, effective therapies with high market demand and significant growth potential.

3. Advanced Neurotechnology for Brain Disorder Treatments

Cutting-edge neurotech devices provide precise brain disorder interventions, addressing unmet medical needs and opening scalable markets in neurology and psychiatry.

4. Precision Medicine Platforms Integrating Genomic Data

Genomic-based precision medicine tailors treatments, improving efficacy and patient care, massively scalable with strong IP advantages in personalized healthcare.

5. Biodegradable Drug Delivery Systems Enhancing Treatment Efficiency

Novel biodegradable carriers optimize drug delivery, reducing side effects and improving compliance, addressing a critical pharmaceutical market need with global scalability.

6. Digital Therapeutics Transforming Chronic Disease Management

Evidence-based digital therapies empower chronic disease patients, lowering healthcare costs and improving outcomes, with scalable software platforms and competitive differentiation.